The U.S. Food and Drug Administration, together with Roche Laboratories, Inc., the maker of Tamiflu (oseltamivir), have informed health care professionals of neuropsychiatric events associated with use of the antiviral drug in patients with influenza. The Tamiflu package insert has been updated to reflect these safety concerns.
